Abatacept

Chemical formula: C₃₄₉₈H₅₄₅₈N₉₂₂O₁₀₉₀S₃₂  Molecular mass: 92,300 g/mol 

Therapeutic indications

Abatacept is indicated for:

Active rheumatoid arthritis

Population group: only adults (18 years old or older)

Abatacept in combination with methotrexate is indicated for:

  • the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.
  • the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polyarticular juvenile idiopathic arthritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Abatacept in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Psoriatic Arthritis

Population group: only adults (18 years old or older)

Abatacept, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Abatacept is contraindicated in the following cases:

Severe and uncontrolled infections

TNF blocking agents

Tumor necrosis factor alpha (TNF-α) inhibitors

Live vaccines should not be given concurrently with abatacept

Vaccines

Pregnancy

Pregnancy

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: ORENCIA Solution for injection
Summary of Product Characteristics (SPC) 2017: ORENCIA Powder for concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈